Checkpoint Therapeutics (NASDAQ:CKPT) PT Lowered to $20.00

Checkpoint Therapeutics (NASDAQ:CKPT) had its price objective decreased by HC Wainwright from $34.00 to $20.00 in a research note released on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Checkpoint Therapeutics Price Performance

CKPT opened at $2.11 on Monday. The stock’s 50 day simple moving average is $2.22 and its 200 day simple moving average is $1.98. Checkpoint Therapeutics has a 1 year low of $1.30 and a 1 year high of $3.62. The firm has a market cap of $75.30 million, a price-to-earnings ratio of -0.76 and a beta of 1.25.

Insider Transactions at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 13,038 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CFO William Garrett Gray sold 13,038 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO James F. Oliviero III sold 24,610 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total value of $50,450.50. Following the completion of the sale, the chief executive officer now owns 1,977,170 shares in the company, valued at $4,053,198.50. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CKPT. Magnus Financial Group LLC purchased a new position in shares of Checkpoint Therapeutics in the 4th quarter valued at approximately $55,000. Choreo LLC purchased a new position in shares of Checkpoint Therapeutics in the 4th quarter valued at approximately $44,000. Armistice Capital LLC lifted its stake in shares of Checkpoint Therapeutics by 17.5% in the 4th quarter. Armistice Capital LLC now owns 2,426,000 shares of the company’s stock valued at $5,556,000 after purchasing an additional 362,000 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Checkpoint Therapeutics by 92.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock valued at $26,000 after purchasing an additional 5,375 shares during the period. Finally, B. Riley Wealth Advisors Inc. lifted its stake in shares of Checkpoint Therapeutics by 232.3% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock valued at $374,000 after purchasing an additional 114,200 shares during the period. Hedge funds and other institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.